75 completed, 11 terminated, 3 unknown, 3 withdrawn. 95 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 95 | Completed 75, Terminated 11, Unknown 3, Withdrawn 3, Active not recruiting 2, Not yet recruiting 1 |
Follow secukinumab: new trials by email Literature Review of secukinumab trials Research Report on secukinumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of Secukinumab Versus Mycophenolate Mofetil in Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (SMART) Secukinumab, Mycophenolate mofetil (MMF) - Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD) | Phase 3 | Not yet recruiting | Chinese PLA General Hospital | 130 | 2026-11-15 | 2026-11-04 |
| A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy Picankibart, Secukinumab, Placebo - Plaque Psoriasis | Phase 3 | Active not recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 308 | 2025-05-27 | 2026-03-25 |
| Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis CMAB015, Secukinumab - Psoriasis | Phase 3 | Completed | Taizhou Mabtech Pharmaceutical Co.,Ltd | 336 | 2024-08-27 | 2026-05-07 |
| Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) Secukinumab - Polymyalgia Rheumatica | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 162 | 2024-06-28 | 2026-10-14 |
| A Study to Evaluate the Efficacy and Safety of LZM012 LZM012, Secukinumab - Psoriasis | Phase 3 | Unknown | Livzon Pharmaceutical Group Inc. | 918 | 2023-08-21 | 2023-11-01 |
| Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy Secukinumab, Placebo - Rotator Cuff Tendinopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 33 | 2023-08-10 | 2026-03-24 |
| Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy Secukinumab, Placebo - Rotator Cuff Tendinopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 60 | 2023-08-02 | 2025-12-18 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR) Secukinumab 300 mg, Secukinumab 150 mg, Placebo to secukinumab - Polymyalgia Rheumatica | Phase 3 | Completed | Novartis Pharmaceuticals | 381 | 2023-03-22 | 2026-06-22 |
| Study of Efficacy and Safety of AIN457/Secukinumab in Patients With Rotator Cuff Tendinopathy Secukinumab, Placebo - Tendinopathy | Phase 3 | Completed | Novartis Pharmaceuticals | 62 | 2022-12-02 | 2026-01-23 |
| Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients BAT2306, EU-approved Cosentyx - Plaque Psoriasis | Phase 3 | Completed | Bio-Thera Solutions | 502 | 2022-10-26 | 2025-04-23 |
| Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission Secukinumab 300 mg, s.c., Placebo to match Secukinumab, s.c. - Giant Cell Arteritis | Phase 3 | Completed | Novartis Pharmaceuticals | 151 | 2022-09-29 | 2026-02-27 |
| Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis Secukinumab - Lupus Nephritis | Phase 3 | Terminated | Novartis Pharmaceuticals | 31 | 2022-08-22 | 2025-05-16 |
| Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA). Secukinumab, Placebo - Active Peripheral Spondyloarthritis (pSpA) | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2022-08-16 | 2023-01-09 | |
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Secukinumab, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2021-11-29 | 2026-04-15 |
| Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA) Secukinumab 300 mg, Placebo, Secukinumab 150 mg - Giant Cell Arteritis (GCA) | Phase 3 | Completed | Novartis Pharmaceuticals | 354 | 2021-10-06 | 2026-03-31 |
| Efficacy and Safety Study of Secukinumab in Chinese Participants With Non-radiographic Axial Spondyloarthritis Secukinumab, Placebo - Non-radiographic Axial Spondyloarthritis | Phase 3 | Completed | Novartis Pharmaceuticals | 137 | 2021-07-21 | 2026-04-09 |
| Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo. AIN457, Secukinumab Placebo - Psoriatic Arthritis | Phase 3 | Completed | Novartis Pharmaceuticals | 41 | 2021-06-24 | 2024-10-09 |
| Efficacy of Secukinumab Compared to Ustekinumab in Adults With Active Psoriatic Arthritis and Failure of TNFα-Inhibitor Treatment Secukinumab, Ustekinumab - Psoriatic Arthritis | Phase 3 | Completed | Novartis Pharmaceuticals | 119 | 2020-12-21 | 2025-10-16 |
| Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis Prednisolone, Sulfasalazine, Leflunomide - Psoriatic Arthritis, Withdrawal | Phase 3 | Unknown | University of Erlangen-Nürnberg Medical School | 270 | 2020-10-19 | 2022-11-14 |
| Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis secukinumab, Placebo - Lupus Nephritis | Phase 3 | Terminated | Novartis Pharmaceuticals | 275 | 2020-07-07 | 2025-05-16 |
Showing 20 of 95. Sign in to see all of them.
Psoriasis (28) · Arthritis, Psoriatic (16) · Plaque, Amyloid (11) · Spondylitis, Ankylosing (11) · Dermatitis (7) · Pruritus (7) · Skin Diseases (7) · Uveitis (7) · Axial Spondyloarthritis (6) · Panuveitis (6) · Uveitis, Intermediate (6) · Uveitis, Posterior (6) · Non-Radiographic Axial Spondyloarthritis (4) · Arthritis (3) · Arthritis, Rheumatoid (3)
Novartis Pharmaceuticals (82) · AbbVie (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Bio-Thera Solutions (1) · Chinese PLA General Hospital (1) · Eli Lilly and Company (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1) · Janssen Research & Development, LLC (1) · Livzon Pharmaceutical Group Inc. (1) · Novartis (1) · Taizhou Mabtech Pharmaceutical Co.,Ltd (1) · Tanja Todberg, MD (1) · UCB Biopharma SRL (1) · University of Erlangen-Nürnberg Medical School (1)
Germany (64) · United States (59) · Spain (45) · United Kingdom (45) · Canada (43) · Italy (43) · Czechia (39) · France (36) · Poland (36) · Belgium (33) · Russia (32) · Hungary (25) · Israel (25) · Australia (24) · Bulgaria (24)
PMID 35305260, PMID 31203228, PMID 37341961, PMID 41965705, PMID 34618347, PMID 27573260, PMID 27576559, PMID 33722947, PMID 34110605, PMID 34795065, PMID 38446397, PMID 23290985, PMID 31087226, PMID 32352653, PMID 33227175, PMID 33351179, PMID 33748660, PMID 34773130, PMID 25007392, PMID 26267726, PMID 26699169, PMID 28544533, PMID 30564451, PMID 30972746, PMID 31801620, PMID 33252266, PMID 34870789, PMID 36334236, PMID 36746171, PMID 39101698, PMID 39411974, PMID 39425517, PMID 40372667, PMID 40489668, PMID 40839197, PMID 41092316, PMID 25243910, PMID 25354738, PMID 26092291, PMID 26135703, PMID 26422723, PMID 27169431, PMID 27390130, PMID 27582421, PMID 27696786, PMID 27965257, PMID 28217871, PMID 28235249, PMID 28580579, PMID 28968735
2015 (7), 2009 (6), 2017 (5), 2016 (4), 2018 (4), 2014 (3), 2019 (3), 2023 (2)